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to the general population. Acquired cardiovascular
diseases such as myocardial infarction and CVA had a
limited role when compared to heart failure.
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Truncating Variants in
Titin Independently
Predict Early Arrhythmias
in Patients With Dilated
Cardiomyopathy
Dilated cardiomyopathy (DCM) has a population
prevalence of w1 in 500 and is associated with prog-
nostically adverse arrhythmias at initial disease pre-
sentation in up to one-third of patients (1). While
FIGURE 1 Overall Survival and Yearly Risk of Cardiovascular Disease in Tetralogy of Fallot
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(A) Overall survival in tetralogy of Fallot (TOF) versus Dutch reference population. Survival curves were created using a delayed entry method with age as time scale for
left-truncated, right-censored data to display overall survival of TOF patients compared to the matched (1:100) Dutch reference cohort. (B) Estimated yearly risk of
cardiovascular disease in tetralogy of Fallot. Estimated yearly risk of cardiovascular disease with age as time scale using smoothed estimates based on B-splines
(bshazard package, R Project for Statistical Computing, Vienna, Austria). CAD ¼ coronary artery disease; CVA ¼ cerebrovascular accident; TIA ¼ transient ischemic
attack; VT ¼ ventricular tachycardia.
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increasing age, male sex, and impaired ventricular
function are established arrhythmic risk factors,
arrhythmias also occur in patients without known
risk factors.
Recently, the advent of high throughput
sequencing technologies has enabled new insights
into the genetic predisposition of DCM. In particular,
titin-truncating variants (TTNtv) are now known to
occur in w15% of cases of DCM and represent the
commonest genetic cause of DCM (2,3). We evaluated
whether genetic information can be used as an addi-
tional tool to identify patients at risk for arrhythmias
by exploring whether there is an association between
TTNtv and the occurrence of arrhythmias at the
time of ﬁrst diagnosis in a large cohort of patients
with DCM.
In total, 572 prospectively recruited patients ful-
ﬁlling diagnostic criteria for DCM by cardiovascular
magnetic resonance were recruited between 2009
and 2015 (68% men, mean age 53.5  14.4 years). All
patients had detailed clinical assessment and
sequencing for novel or rare (Exome Aggregation
Consortium frequency <0.001) truncating variants in
constitutively expressed TTN exons. Focusing on early
arrhythmic risk, data on arrhythmia history (atrial
ﬁbrillation [AF], nonsustained ventricular tachycardia
[VT], and sustained VT) on recruitment to the study
were collated from hospital and primary care notes.
Multivariable logistic regression was used to evaluate
variables associated with arrhythmias at presentation.
In the cohort, mean left ventricular ejection frac-
tion was 39.0  12.6% (median ¼ 40%; interquartile
range: 29% to 49%). Midwall late gadolinium
enhancement (LGE) myocardial ﬁbrosis was detected
in 198 patients (35%). A family history of DCM was
found in 82 patients (14%) and a family history of
sudden cardiac death in 76 patients (13%).
Arrhythmias prior to recruitment were docu-
mented in 196 (34%) patients. Speciﬁcally, 139
(24%) patients had conﬁrmed AF, 69 (12%) patients
had conﬁrmed nonsustained VT and 11 (2%) pa-
tients had conﬁrmed sustained VT. Of these, 22
patients had more than 1 type of arrhythmia: 15
had both AF and nonsustained VT; 1 had both AF
and sustained VT; 5 had both sustained VT and
nonsustained VT; and 1 had AF, nonsustained VT,
and sustained VT.
Patients with arrhythmia were more likely to be
older, be men, and have worse biventricular function
(age 58.7  12.2 years vs. 50.8  14.7 years; 161 [82.1%]
men vs. 227 [60.4%] men; left ventricular ejection
fraction 36.1  12.1% vs. 40.4  12.7%; right ventric-
ular ejection fraction 33.9  13.7% vs. 40.7  13.8%;
p < 0.0001 for all). Although LGE is associated with
arrhythmia later in established disease, there was no
signiﬁcant difference in the proportion of patients
with LGE between the arrhythmia positive and
negative groups at presentation (122 [32.4%] vs. 76
[38.8%]; p ¼ 0.16).
TTNtv were observed in 13.3% (n ¼ 26) of patients
with a history of arrhythmia compared to 8% (n ¼ 30)
of patients without a history of arrhythmia (p ¼ 0.05).
Conversely, an arrhythmia was documented in 26
patients (46%) with TTNtv compared to 170 patients
(33%) without TTNtv (p ¼ 0.05). In exploratory uni-
variable analysis, the presence of a TTNtv was pre-
dictive of baseline arrhythmia in DCM patients
(unadjusted odds ratio: 1.76; 95% conﬁdence interval:
1.01 to 3.08; p ¼ 0.05) (Table 1).
This association was stronger in multivariable
regression analyses, adjusting for variables associated
with baseline arrhythmia in this cohort (age, gender,
indexed left atrial volume, and ventricular function).
TTNtv independently predicted early arrhythmias in
DCM (adjusted odds ratio: 2.90; 95% conﬁdence
interval: 1.48 to 5.78; p ¼ 0.002) (Table 1).
Variants in LMNA are found in up to 4% of DCM
cases and are strongly associated with an arrhythmic
phenotype. In sensitivity analyses to control for
potential LMNA effects, TTNtv remained predictive of
arrhythmia after 12 patients with rare (Exome
Aggregation Consortium frequency <0.001), protein-
altering LMNA variants were excluded from analysis
(adjusted odds ratio: 2.88; 95% conﬁdence interval:
1.44 to 5.81; p ¼ 0.003). Putative DCM variants in
other genes were not evaluated due to the small
number of affected individuals and no prior associa-
tions with arrhythmia.
TABLE 1 Results of Logistic Regression Analysis
Variable
Unadjusted Analysis Adjusted Analysis
OR p Value
95% Conﬁdence
Interval OR p Value
95% Conﬁdence
Interval
Age (per 10 yrs) 1.53 <0.0001 1.33–1.76 1.60 <0.0001 1.36–1.89
Male 3.02 <0.0001 2.00–4.65 2.33 <0.0001 1.44–3.83
LVEF (per 10%) 0.76 <0.001 0.66–0.87 — — —
RVEF (per 10%) 0.71 <0.0001 0.62–0.80 0.79 <0.0001 0.67–0.92
TTNtv positive 1.76 0.05 1.01–3.08 2.90 0.002 1.48–5.78
LAVi (per 1 ml/m2) 1.03 <0.0001 1.02–1.04 1.03 <0.0001 1.02–1.04
LGE present 1.32 0.13 0.92–1.89 — — —
FHx DCM 0.59 0.06 0.34–1.00 — — —
FHx SCD 0.62 0.09 0.35–1.06 — — —
Results of logistic regression model of predictors of early arrhythmias in dilated cardiomyopathy (DCM). Variables
with p < 0.10 from the univariable analysis were considered for inclusion in an optimized multivariable model,
created using backward stepwise selection until only signiﬁcant variables remained. Truncating variant in titin
(TTNtv) was added to this optimized model.
FHx ¼ family history; LAVi ¼ indexed left atrial volume; LGE ¼ midwall ﬁbrosis late gadolinium enhancement;
LVEF ¼ left ventricular ejection fraction; RVEF ¼ right ventricular ejection fraction; SCD ¼ sudden cardiac death.
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Our data demonstrate that TTNtv are associated
with early arrhythmic risk in patients with DCM, in-
dependent of conventional arrhythmic risk factors.
Although all patients were identiﬁed prospectively,
baseline arrhythmia data were collected retrospec-
tively and we have consolidated ventricular and atrial
arrhythmias into 1 arrhythmia category, with a
modest absolute increase in arrhythmic risk (13%).
However, these ﬁndings have relevance for all DCM
cases with TTNtv, representingw15% of all DCM. This
study provides insights into the arrhythmic burden
associated with TTNtv and highlights additional
genetic tools for the stratiﬁcation of high-risk DCM
patients.
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Neurocognitive Risk With
PCSK9 Inhibitors
Need for More Robust Evidence
In a pooled analysis of 14 trials of alirocumab,
Robinson et al. (1) reported the safety of alirocumab
even with very low levels of low-density lipoprotein
cholesterol (LDL). They found that 25% of the
patients who received alirocumab had an LDL
level <25 mg/dl with the median duration of low
LDL level being w43 weeks. In these patients with
very low LDL levels, they found no increase in
treatment-emergent serious adverse events or
neurocognitive adverse effects (NCE). We recognize
the overall safety of alirocumab as demonstrated in
their analysis, but there are some limitations that
need to be highlighted. Out of the 14 trials pooled, 4
were phase 2 studies with a total duration between
8 and 12 weeks and 3 were phase 3 studies with a
duration of 24 weeks. This is a very short duration
to assess the safety of an agent that will be required
for life-long therapy. Seven trials had a longer
follow-up, between 52 and 104 weeks, but almost all
were limited by their sample size. Almost all of
these trials were small-size, early phase studies
designed to demonstrate LDL lowering efﬁcacy.
The only trial (ODYSSEY LONG TERM [Long-term
Safety and Tolerability of Alirocumab in High Car-
diovascular Risk Patients with Hypercholesterolemia
Not Adequately Controlled with Their Lipid Modi-
fying Therapy]) designed to assess clinical outcomes
suggested an increased risk of NCEs (2). Similarly,
the only large open-label trial (OSLER [Open Label
Study of Long Term Evaluation Against LDL-C
Trial]) to assess the safety and clinical efﬁcacy of
evolocumab, the other proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitor, suggested
an increased risk of NCE (3). Pooling only these 2
trials, which had a larger sample size and a longer
follow-up, suggested an increased risk of NCE as
reported in 2 recent meta-analyses (4,5). However,
these analyses were also limited by lack of data
on baseline cognition of the patients included in
the studies and lack of an objective assessment of
cognitive ability.
As mentioned, the current evidence is limited.
Also, the overall low incidence of NCEs in control and
PCSK9-treated groups does not preclude the use of
PCSK9 inhibitors in appropriate patient populations.
But there should be a discussion with the patient
regarding the risks and beneﬁts of the therapeutic
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